Experience
Sun Pharmaceutical Inds.
Eli Lilly and Company
Lead trial and appellate counsel in action to prevent generic competition for anti-cancer drug Gemzar®. One patent sustained. Second method patent found invalid based on expansion of law of double patenting. Left standing on petition for rehearing by 5-4 vote.
Sun Pharmaceutical Inds. v. Eli Lilly and Company, 10-1105, Fed. Cir., Judges Bryson, Gajarsa, Prost
Sun Pharmaceutical Inds. v. Eli Lilly and Company, 2:07-cv-15087, E.D. Mich., Judges Steeh, Whalen
Eli Lilly and Co. v. Apotex Inc.
Eli Lilly and Company
Eli Lilly and Company v. Sicor Pharmaceuticals, Inc.
Eli Lilly and Company
Eli Lilly & Co. v. Wockhardt Ltd.
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Synthon Pharmaceuticals, Inc. v. Eli Lilly and Co.
Eli Lilly and Co.; ICOS
Eli Lilly and Company
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.